- Home
- RPD vs CDTX Comparison
RPD vs CDTX Comparison
Compare RPD & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- CDTX
- Stock Information
- Founded
- RPD 2000
- CDTX 2012
- Country
- RPD United States
- CDTX United States
- Employees
- RPD N/A
- CDTX N/A
- Industry
- RPD Computer Software: Prepackaged Software
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPD Technology
- CDTX Health Care
- Exchange
- RPD Nasdaq
- CDTX Nasdaq
- Market Cap
- RPD 1.5B
- CDTX 1.4B
- IPO Year
- RPD 2015
- CDTX 2015
- Fundamental
- Price
- RPD $20.91
- CDTX $62.71
- Analyst Decision
- RPD Hold
- CDTX Strong Buy
- Analyst Count
- RPD 19
- CDTX 12
- Target Price
- RPD $28.11
- CDTX $57.00
- AVG Volume (30 Days)
- RPD 975.3K
- CDTX 481.5K
- Earning Date
- RPD 08-07-2025
- CDTX 08-07-2025
- Dividend Yield
- RPD N/A
- CDTX N/A
- EPS Growth
- RPD N/A
- CDTX N/A
- EPS
- RPD 0.43
- CDTX N/A
- Revenue
- RPD $855,361,000.00
- CDTX N/A
- Revenue This Year
- RPD $2.82
- CDTX N/A
- Revenue Next Year
- RPD $3.94
- CDTX N/A
- P/E Ratio
- RPD $48.53
- CDTX N/A
- Revenue Growth
- RPD 4.67
- CDTX N/A
- 52 Week Low
- RPD $17.83
- CDTX $10.14
- 52 Week High
- RPD $44.48
- CDTX $66.95
- Technical
- Relative Strength Index (RSI)
- RPD 49.95
- CDTX 71.50
- Support Level
- RPD $17.83
- CDTX $60.30
- Resistance Level
- RPD $20.86
- CDTX $64.26
- Average True Range (ATR)
- RPD 1.00
- CDTX 2.96
- MACD
- RPD 0.07
- CDTX -0.80
- Stochastic Oscillator
- RPD 68.99
- CDTX 97.51
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.